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ABSTRACT
Introduction: This study aimed at determining
the clinical safety and efficacy of insulin
detemir (IDet) in combination with oral anti-
diabetic drugs (OADs) in type 2 diabetes (T2D)
patients from four Near East Countries (Israel,
Jordan, Pakistan and Lebanon).
Methods: This prospective observational study
included T2D patients previously on OADs and
newly diagnosed patients initiating IDet with or
without OADs, at the discretion of physicians.
Safety objectives included evaluation of
hypoglycemia and adverse drug reactions
(ADRs) from baseline to Week 24. EfficacyClinical Trial Registration Number: NCT00842192.
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outcomes included baseline to Week 24 changes
in glucose control parameters (glycated
hemoglobin [HbA1c], fasting plasma glucose
[FPG] and post-breakfast post-prandial plasma
glucose [PPPG]). Change in body weight during
this period was also assessed.
Results: A total of 2,155 patients (mean ± SD:
age 57.1 ± 11.0 years, BMI 29.4 ± 5.1 kg/m2,
average diabetes duration 9.2 ± 5.4 years)
were included. IDet dose at baseline was 0.20
± 0.09 U/kg titrated up to 0.34 ± 0.14 U/kg by
Week 24. From baseline to Week 24, the total
number of hypoglycemic episodes increased
from 1.30 to 1.37 events/patient-year, while
major hypoglycemic episodes decreased from
0.15 to 0.02 events/patient-year. A total of 9
ADRs were reported, of which one event
was a serious ADR. Statistically significant
improvements in glucose control were
reported from baseline to Week 24 (HbA1c:
9.6 ± 1.6% vs. 7.6 ± 1.1%; FPG: 201.5 ± 59.5
mg/dL vs. 124.9 ± 31.6 mg/dL; PPPG: 264.2 ±
65.7 mg/dL vs. 167.2 ± 36.8 mg/dL; all p \
0.0001). Body weight did not change
significantly after 24 weeks of IDet therapy.
Conclusion: IDet therapy in combination with
OADs improved glycemic control without
increasing the risk of hypoglycemia or weight
gain.
Keywords: Insulin detemir; Near East;
Observational study; Type 2 diabetes
INTRODUCTION
Managing type 2 diabetes (T2D) is a
challenging task due to the continual decline
in beta-cell function that occurs. This
progressive debilitating condition ultimately
mandates the use of insulin in most, if not
all patients [1]. Timely initiation and active
intensification of insulin is highly
recommended to decrease the risk of long-
term complications [2]. The American Diabetes
Association recommends a target glycated
hemoglobin (HbA1c) level of \7.0% as an
established standard of good glycemic control
[3]. Despite these guidelines, it has been
observed that initiation and intensification of
insulin in routine clinical practice is often
delayed over fears of hypoglycemia, weight
gain and effects on patients’ quality of life
(QoL) [1, 4]. Other factors such as insulin
availability, needle phobia and economic
considerations are also possible barriers that
can have a significant impact on patient
adherence to treatment [5].
Conventional basal insulins, such as neutral
protamine Hagedorn (NPH) and insulin
glargine have variable absorption kinetics
resulting in increased within-patient blood
glucose variability and an associated risk of
hypoglycemia [6, 7]. Also, the weight gain
associated with conventional insulin therapy
may increase blood pressure and worsen lipid
profiles [8]. The development of long-acting
basal insulin analogs, such as insulin detemir
(IDet), with improved pharmacokinetics has
been shown to have a positive effect on the
balance between effective glycemic control and
hypoglycemic risk [9].
IDet is able to closely mimic endogenous
insulin secretion and has a prolonged time-
action profile due to its self-association and
albumin-binding properties [10]. It is prescribed
once- or twice-daily as an adjunct to oral anti-
diabetic drugs (OADs), glucagon-like peptide-1
analogs or as combination therapy with short-
or rapid-acting insulins [11]. Previously, it has
been demonstrated that IDet therapy results in
lower within-subject variability of fasting
plasma glucose (FPG) when compared with
NPH insulin therapy [12]. Also, the
400 Diabetes Ther (2013) 4:399–408
123
effectiveness of glucose control with IDet has
been observed with a reduced risk of
hypoglycemia and no concerns about weight
gain [13, 14].
The clinical benefits of insulin analogs,
including IDet, could become an integral part
of managing T2D, a disease that has reached
epidemic proportions worldwide [15].
Developing countries from the Near East
region face a serious socioeconomic burden
of increasing diabetes incidence. According to
the International Diabetes Federation, in 2012,
the prevalence of diabetes in Israel, Jordan,
Lebanon and Pakistan was 7.85%, 11.62%,
17.04% and 7.89%, respectively [15].
Additionally, Lebanon is listed among the top
10 countries for diabetes prevalence worldwide
[16]. Active measures to control and manage
this disease are warranted. In order to increase
awareness and provide appropriate guidance
on T2D management the availability of local
clinical data is essential. This 24-week
observational study was thus conducted in
T2D patients from four Near East Countries
(Israel, Lebanon, Jordan and Pakistan) with an
aim to evaluate the post-authorization




This multinational, prospective, observational
study evaluated the safety and efficacy of
24 weeks of treatment with IDet (Levemir,
Novo Nordisk, Bagsvaerd, Denmark) in T2D
patients from four Near East countries (Israel,
Jordan, Lebanon and Pakistan) between April
2009 and August 2010. Patients prescribed IDet
at the discretion of their consulting physicians,
based on clinical judgement and country-
specific Summary of Product Characteristics or
Product Information reports, were enrolled in
the study. Any subsequent changes in dose or
frequency of administration of IDet or OADs
were determined by the physician. IDet was
commercially available and prescribed in
accordance with local healthcare regulations.
There were no predefined study procedures and
all assessments were performed as part of
routine clinical care. The physicians evaluated
patients at baseline, the interim visit
(approximately 12 weeks post-baseline visit)
and final visit (approximately 24 weeks post-
baseline visit).
Patients
This study included any T2D patient previously
treated with one or more OADs (metformin,
sulfonylureas, repaglinide, thiazolidinediones)
or newly diagnosed T2D patients starting
IDet ± OAD therapy. Patients currently being
treated with IDet or any other insulin regimen,
including bolus therapy, were excluded from
the study. Also, patients with a reported
hypersensitivity to IDet or any of its excipients
were not included in this study. The study did
not include women who were pregnant, breast
feeding, had the intention of becoming
pregnant within 6 months or those of
childbearing potential and not using adequate
contraceptive methods.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was
obtained from all patients for being included
in the study.
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Outcomes
The primary safety objective was to evaluate
change in the number of hypoglycemicepisodes
from the 4 weeks preceding the baseline visit
compared with after 24 weeks of IDet treatment.
Information on hypoglycemic episodes was
collected based on patients’ recall of the last
4 weeks before baseline and Week 24. Minor
hypoglycemic events were described as
symptoms of hypoglycemia with confirmation
by plasma glucose measurement \3.1 mmol/L
(56 mg/dL) and which was handled by the
patient himself/herself, or any asymptomatic
plasma glucose level \3.1 mmol/L (56 mg/dL).
Nocturnal hypoglycemic events were defined as
individualized symptomatic events consistent
with hypoglycemia that occurred while the
patient was asleep, between bedtime after the
evening insulin injection and before getting up
in the morning (if relevant, before morning
determination of FPG and before morning
injection). Severe central nervous system
symptoms consistent with hypoglycemia in
which the patient was unable to treat himself/
herself, or reversal of symptoms after either
glucagon or intravenous glucose administration
were categorized as major hypoglycemic events.
Additionally, hypoglycemia due to the fasting
regimen, Ramadan, was also reported. The
incidence of adverse drug reactions (ADRs) was
reported as the secondary safety objective.
The primary efficacy endpoint was to
determine the effects of IDet on glycemic
control as reflected by changes in HbA1c levels
after 24 weeks of treatment. Secondary
endpoints included evaluation of the number
of patients achieving HbA1c targets of \7.0%
and B6.5%; changes in FPG, post-breakfast post-
prandial plasma glucose (PPPG) and body
weight; and FPG variability from baseline to
Week 24. FPG variability was defined as the
standard deviation (SD) of the three most
recent FPG values.
Statistical Analysis
Approximately 2,000 patients were considered
sufficient to evaluate primarily the safety of IDet
in this study. This sample size was estimated to
provide a statistical power greater than 99% to
detect a 1.0% change in HbA1c from baseline
based on a standard deviation of 1.2 and an
estimated drop-out rate of 20%.
Patients who had received at least one dose
of IDet and reported any post-baseline data were
included in the full analysis set. Demographic
characteristics, HbA1c, FPG, PPG and body
weight were summarized using descriptive
statistics. Categorical data were summarized
using the number (n) and percentage. The
paired t test was used to analyze the change
from baseline to Week 24 in HbA1c, FPG, PPPG
and body weight. The change in the proportion
of patients with HbA1c \7.0% or B6.5% was
evaluated using the Chi square test. All
statistical analyses were based on two-sided
tests and a significance level of a = 0.05. All
data were analyzed using SAS Version 9.1.3




Of the 2,155 patients enrolled, 2,106 (97.7%)
were exposed to the study drug. A total of 1,843
(85.5%) patients completed the study and 263
(12.2%) withdrew from the study. The reasons
for premature discontinuation from the study
included lost contact (146 patients, 6.8%),
ADRs (6 patients, 0.3%) and other reasons
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(111 patients, 5.2%), which included non-
compliance, consent withdrawal and therapy
switch to OADs or other insulins. The
demographic characteristics along with OAD
use at baseline for the entire cohort and patients
that withdrew are presented in Table 1. Prior
to study enrolment, biguanides (84.9%),
sulfonylureas (78.0%) and thiazolidinediones
(17.9%) were the most commonly
administered OADs. The most common
physician’s reason to initiate IDet therapy was
to improve glycemic control in 2,038 patients
(96.8%), while the other common reasons were
to reduce plasma glucose variability and to
control unstable diabetes in 827 (39.3%) and
656 (31.1%) patients, respectively.
Insulin Dose
Mean (±SD) IDet dose at baseline was
0.20 ± 0.09 U/kg (15.6 ± 7.1 U/day), titrated
up to 0.34 ± 0.14 U/kg (27.1 ± 11.4 U/day) by
Week 24.
Hypoglycemia
Overall, major, minor and nocturnal
hypoglycemic events and hypoglycemic events
due to the fasting regimen, Ramadan, are
reported in Table 2. The incidence of
hypoglycemia (all events) appeared to increase
slightly during the study, from 1.37 events/
patient-year at Week 24 compared with 1.30
events/patient-year at baseline. The rate of
major hypoglycemic episodes appeared to be
lower at Week 24 (0.02 events/patient-year) in
comparison with baseline (0.15 events/patient-
year). The rate of nocturnal hypoglycemia
appeared similar at baseline and Week 24 (0.40
and 0.39 events/patient-year, respectively). The
rate of hypoglycemia due to fasting in Ramadan
also appeared similar at baseline and Week
24 (0.07 and 0.06 events/patient-year,
respectively).








Age (years)b 57.1 (11.0) 57.1 (11.8)
Body weight (kg)b 80.2 (14.1) 80.5 (13.6)
BMI (kg/m2)b 29.4 (5.1) 29.7 (5.0)
Diabetes duration
(years)b
9.2 (5.4) 9.5 (5.8)
HbA1c (%)
b 9.6 (1.6) 9.7 (1.8)
OADs at baseline, n (%)
Biguanides 1,687 (80.1) 263 (100.0)
Sulfonylureas 1,497 (71.1) 155 (58.9)
Thiazolidinediones 292 (13.9) 21 (8.0)
BMI body mass index, HbA1c glycated hemoglobin A1c,
OAD oral anti-diabetic drug, SD standard deviation
a Patients had received at least one dose of IDet
b Data are mean (SD)















Hypoglycemic episodes were collected based on patients’
recall of the last 4 weeks before baseline and Week 24
a Fasting regimen at Ramadan
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Adverse Drug Reactions
A total of 9 ADRs were reported in 9 patients
(0.4%) during the study. Of these, one event in
one patient was a serious ADR of chronic renal
failure. In all, 12 treatment emergent adverse
events were reported in 11 patients (0.5%). Of
the 6 ADRs that led to discontinuation of IDet,
5 events (3 drug hypersensitivity/drug allergy;
1 pruritus; 1 drug eruption) were considered
probably related to IDet, while one event of
bone pain was considered possibly related to
IDet. These events were mild to moderate in
intensity.
Body Weight
Mean body weight did not change significantly
from baseline (80.5 ± 13.8 kg) to Week 24
(80.4 ± 13.5 kg, p = 0.567).
Glucose Control
Mean HbA1c levels improved significantly from
9.6 ± 1.6% at baseline to 7.6 ± 1.1% at Week 24
(mean change, -2.0 ± 1.6%, p\0.0001)
(Table 3). HbA1c \7.0% was reported in 424 of
1,574 patients (26.9%) at Week 24 compared
with 29 of 1,896 patients (1.5%) at baseline.
HbA1c B6.5% was achieved by 16 of 1,896
patients (0.8%) at baseline, increasing to 189
of 1,574 patients (12.0%) by Week 24.
At Week 24, there was a statistically
significant mean decrease of 76.6 ± 62.5 mg/dL
in FPG (p\0.0001, Table 3). The decrease in
FPG variability from baseline to Week 24 was
statistically significant (-10.1 ± 19.8 mg/dL,
p\0.0001) as was the reduction in post-
breakfast PPPG levels (Week 24, 167.2 ±
36.8 mg/dL vs baseline, 264.2 ± 65.7 mg/dL,
p\0.0001, Table 3).
DISCUSSION
Previously, it has been established that adding
basal insulin to existing OAD therapy is an
effective treatment strategy to manage
uncontrolled T2D [17]. This study assessed the
effects of IDet in combination with OADs in
patients with T2D from Israel, Lebanon, Jordan
and Pakistan. Introducing IDet therapy was well
tolerated and resulted in marked improvements
in glucose control after 24 weeks.
Baseline glycemic control in this cohort was
poor. The average baseline HbA1c level was
9.6%, while FPG and post-breakfast PPPG
levels were 201.5 mg/dL and 264.2 mg/dL,
respectively. This calls for an imperative need
to design and implement more aggressive
strategies to optimize T2D management in
Table 3 Baseline and 24-week data for glycemic parameters
Parameter n Baseline Week 24 Change p value
HbA1c (%) 1,460 9.6 (1.6) 7.6 (1.1) -2.0 (1.6) \0.0001
FPG (mg/dL) 1,532 201.5 (59.5) 124.9 (31.6) -76.6 (62.5) \0.0001
FPG variability (mg/dL) 443 22.1 (18.6) 12.0 (11.7) -10.1 (19.8) \0.0001
PPPG (mg/dL) 940 264.2 (65.7) 167.2 (36.8) -97.1 (68.9) \0.0001
Data are mean (SD). FPG variability was deﬁned as the SD of the three most recent FPG values
FPG fasting plasma glucose, HbA1c glycated hemoglobin A1c, PPPG postprandial plasma glucose, SD standard deviation
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routine clinical practice in the Near East
countries.
Initiating IDet significantly improved HbA1c,
FPG and PPPG following 24 weeks of treatment.
A total of 424 patients (26.9%) achieved the
target HbA1c level of \7.0% with 189 patients
(12.0%) achieving the more aggressive target of
HbA1c B6.5% after 24 weeks of treatment.
Additionally, there were indications of a
reduction in plasma glucose fluctuation as
assessed by evaluating the standard deviations
of the three most recent FPG levels. These
improvements were seen alongside a low risk
of hypoglycemia. As an expected outcome with
first-time insulin initiation, there was a
marginal increase in the rate of overall
hypoglycemia from baseline to Week 24.
However, the incidence of major
hypoglycemia was lower at Week 24 compared
with baseline. The incidence of major
hypoglycemia could be reduced due to initial
responses to a change in therapy. Also, this
study included only insulin-naı¨ve patients who
have a much lower rate of hypoglycemia
compared with prior insulin users [18].
Nevertheless, we also acknowledge that a recall
bias may have been introduced that could have
masked the actual incidence of hypoglycemia.
The clinical safety and efficacy of treatment was
demonstrated without administering high
doses of IDet (0.20 U/kg to 0.34 U/kg)
throughout the study period. Although the
actual IDet dose in this study was lower than
that reported in interventional trials [19, 20], a
significant change in glycemic control was
observed. This positive response to therapy
could also encourage physicians to resort to
more active therapy intensification, leading to
enhanced management of T2D.
Previously, it has been reported that every
2.5% decrease in HbA1c is associated with a
weight gain of *5 kg [21]. In contrast, average
body weight remained fairly constant in our
study despite a significant 2.0% decrease in
mean HbA1c level. Raslova´ et al. [22] also
demonstrated that patients on IDet
experienced less weight gain than those on
NPH insulin in a pooled analysis of 900 patients
with T2D. Several theories have been proposed
to justify the low weight gain observed with
IDet therapy. The low glucose variability
reported with IDet therapy may minimize
defensive snacking resulting in decreased
weight gain. Also, IDet may induce the satiety
signaling mechanism in the central nervous
system or suppress adipogenesis in the
peripheral tissues due to its albumin-binding
properties [23]. IDet has a prolonged
therapeutic action owing to its strong
tendency to self-associate and remain highly
bound to albumin in the subcutaneous depot
[24]. Nevertheless, the exact mechanism of
action resulting in low weight gain following
IDet therapy has yet to be elucidated.
The United Kingdom Prospective Diabetes
study demonstrated that 53% of patients
treated with sulfonylurea monotherapy
required insulin over a period of 6 years [25].
The gradual decline in beta-cell mass and
function in patients with T2D is correlated
with an increase in HbA1c levels, even after the
use of more than one OAD [26]. Hence, insulin
therapy becomes mandatory for all patients.
However, intensification with insulin therapy
also increases the risk of hypoglycemia. Our
study demonstrates that initiating IDet therapy
effectively enhances glycemic control, without
increasing the risk of hypoglycemia and weight
gain, in line with the data from randomized
controlled trials [19, 27].
The observational design of the current
study has limitations such as the lack of a
control arm, retrospective data collection
methods, non-standardization of reported data
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and possible recall bias for the incidence of
hypoglycemia. However, the results obtained
are useful for evaluating a treatment in real-life
setting rather than in randomized controlled
trials in which the data are often influenced by
the restricted sample of patients enrolled. Also,
observational studies are considered to be more
useful in evaluating the post-authorization
safety profile of drugs compared with
randomized controlled trials [28]. This study
included patients on OAD therapy alone and
newly diagnosed patients starting IDet ? OAD
therapy, irrespective of their concomitant
medical conditions or other baseline criteria,
thus representing situations that community-
based practitioners encounter. The data
evaluated in this study may thus be useful in
guiding the optimization of T2D management
in routine practice.
CONCLUSION
In summary, the results of this observational
study in the Near East region countries showed
that treatment initiation with a long-acting
basal analog, IDet, in combination with OAD
therapy, can be a safe and effective treatment
strategy for T2D patients.
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